Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
Status:
Not yet recruiting
Trial end date:
2023-12-15
Target enrollment:
Participant gender:
Summary
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics,
pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody
(AQP4-IgG) positive NMOSD.